deliverydaa.blogg.se

It’s important to note that Paxlovid (the brand name for the drug, which is made up of two generic medications-nirmatrelvir and ritonavir) isn’t the only pill available to treat COVID-19. It shows clear benefit, and it really can prevent hospitalization and death in people who are at high risk.” “It's really our first efficacious oral antiviral pill for this virus. “I think it is the beginning of a ‘game-changer,’” says Scott Roberts, MD, a Yale Medicine infectious diseases specialist.

government while there is a public health emergency), and, perhaps most reassuring, it is expected to work against the Omicron variant. It’s cheaper than many other COVID-19 drugs (it’s provided for free by the U.S. Studies outside of the laboratory have since confirmed Paxlovid’s effectiveness among people who have been vaccinated. The drug, developed by Pfizer, has a lot of positives: It had an 89% reduction in the risk of hospitalization and death in unvaccinated people in the clinical trial that supported the EUA, a number that was high enough to prompt the National Institutes of Health (NIH) to prioritize it over other COVID-19 treatments.

So, if you test positive for the coronavirus and you are eligible to take the pills, you can take them at home and lower your risk of going to the hospital. Paxlovid is an oral antiviral pill that can be taken at home to help keep high-risk patients from getting so sick that they need to be hospitalized. The drug was granted an emergency use authorization (EUA) by the Food and Drug Administration (FDA) in December for anyone ages 12 and older who weighs at least 88 pounds, and is at high risk for severe disease.

Paxlovid is the latest COVID-19 treatment that’s been all over the news. Because information about COVID-19 changes rapidly, we encourage you to visit the websites of the Centers for Disease Control & Prevention (CDC), World Health Organization (WHO), and your state and local government for the latest information. Note: Information in this article was accurate at the time of original publication.